Pilot Study of Origanum majoranaTea on Oxidant/Antioxidant Stress Biomarkers in Parkinson disorder North-African Volunteers - Trial PACTR202205801626909

Timeline & Enrollment

Summary

BACKGROUNDParkinson’s disease (PD) is the second common chronic neurodegenerative disease after Alzheimer’s disease, characterized by the degeneration of dopaminergic nigro-striatal neurones to the corpus striatum, that induce non-motor and motor symptoms. Many researches incriminated Oxidative changes is one of the important factor contributors in the genesis of Parkinson’s disease. During the pathogenesis of PD, inflammation and oxidative stress play critical roles in the cascade of events leading to loss of dopaminergic neurons in PD. This phenomenon seems to be induced mainly by changes in iron content of the brain, mitochondrial dysfunction, monoamine oxidase (MAO) activation, or even by changes in the antioxidant defense system include superoxide dismutase (SOD), catalase, glutathione, and uric acid (UA). Despite the link between oxidative damage and the progression of PD, to date, the effects obtained with antioxidant therapies are modest. Antioxidant molecules have been considered attractive therapeutic drugs to cure PD. However, no direct antioxidant, such as vitamin C, vitamin E, and coenzyme Q10, has shown significant effects on modification in PD patients. Previous works, reported that several plant extracts are powerful in PD risk. The alternative treatment of PD is the therapy of herbal medicine (HM). The use of natural products due to their safety, efficiency, acceptability and comparably fewer side effects than chemical drugs. They contain active components that could be effective on treatment or delay neurodegeneration progression in PD. From these studies, our hypothesis is to test the effect of Origanum majorana (Om) on antioxidant fractions levels and the possibility to slower PD progression. In the other hand, in the present work we assessed the potential protective role of Origanum majorana through the stimulation of the antioxidant system in order to reduce and improve symptoms related to Parkinson's disease.Origanum majorana L an evergreen tree of Lamiaceae family known by the name’s sweet marjoram or marjoram. Origanum majorana has several therapeutic properties. It is known to have a beneficial effect as an infusion of the fresh herb in treating cramps, depression, dizziness, upset stomach, indigestion, gastrointestinal disorders, colic, migraine, nervous complaints, paroxysmal coughs and as a diuretic. To the best of our knowledge, there is no scientific data that highlights the therapeutic effects of Origanum majorana infusion on PD patients in particular its impact on the increased anti-oxidant activity in blood plasma.OBJECTIVES. The purpose of this randomized, double-blind controlled trial, which includes two groups [Experimental group (EG), control group (CG)], was to investigate the effect of Origanum majorana tea consumption on oxidant/antioxidant data in humans. The null hypothesis was that the two groups will have similar SOD values, 30 days after the intervention. The primary outcome of this exploratory investigation was to identify SOD biomarker that would be affected by Origanum majorana tea consumption. This is to reduce or delay the propagation of disease and the secondary were Catalase, CP: Carbonylated proteins and UA: Uric acid analysis.

ICD-10 Classifications